Month: March 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space

Written by Customer Service on March 7, 2022. Posted in Public Companies.

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) — NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/JeGwq There’s strong belief that different classes of psychedelics, such as ketamine, psilocybin, DMT and MDMA, can be developed for a wide range of unmet medical needs. These needs may include hard-to-treat disease and disorders such as anxiety, depression, addiction and post-traumatic stress, among others. In aggregate, mental health maladies affect more than 900 million people globally with direct and indirect economic costs of a staggering $2.5 trillion. Today, therapeutics protocols...

RAMSAY SANTE : Half-year Financial Report as at end of December 2021 disposal

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

Paris, February 24, 2022 RAMSAY SANTE Half-year Financial Report as at end of December 2021 disposal This document is available on RAMSAY SANTE Internet site : http://www.ramsaygds.com About Ramsay Santé : After the successfull acquisition of Capio AB Group in 2018, Ramsay Santé is becoming one of the leaders of the hospitalisation and primary care in Europe with 36 000 employees and 8 600 practitioners serving 7 million patients in our 350 facilities in 5 countries : France, Sweden, Norway, Denmark and Italy. Ramsay Santé offers almost all medical and surgical specialities in three business areas : general hospitals (medicine – surgery – obstetric), follow-up care and rehabilitation clinics, mental health. In all its territories, the group contributes to missions of public service and to the territorial sanitory...

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study expected in Q1 2023 Current cash provides runway into 2024 and through multiple expected key clinical milestones SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2021 financial results and highlighted recent corporate achievements. “Our clinical and corporate achievements in 2021 have set a solid foundation for a potentially transformational next 12 months,” said Jeremy Bender,...

GGTOOR, Inc. (OTCMKTS:GTOR) Announces Management Report for the Week Ended March 5, 2022

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

Metaverse – Stay Tuned THOMASVILLE, GA, March 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — GGTOOR, Inc. (OTCMKTS:GTOR) (“GGTOOR, Inc.”, “GTOR”, or the “Company”), an emerging leader in the eSports markets, announces this week, over 1,250 players registered to compete in our events! John V Whitman Jr., GGToor CEO, said, “On November 15, 2021, the Company announced for the twelve months ended May 31, 2021, total website impressions were a dismal 107,995 or just 8,999 per month. The five months ended May 31, 2021, the Company had grown to an impressive 9,319,019 impressions or an average of 1,863,803 per month. Today, I am absolutely proud to announce web impressions for January 2022 were 6,576,351 and February 2022, web impressions were 7,371,957. In 2022 the Company is averaging 6,974,154 web impressions per month vs 8,999...

Electric Vehicle Supply Equipment Market Size to Hit USD 208.34 Billion by 2028 | Exhibit a CAGR of 31.1%

Written by Customer Service on March 7, 2022. Posted in Mergers And Acquisitions.

Electric Vehicle Supply Equipment Market growth is boosted by increasing electric vehicles penetration and favorable government policies Pune, India, March 07, 2022 (GLOBE NEWSWIRE) — Electric Vehicle Supply Equipment market size is projected to reach USD 208.34 billion in 2028, at a CAGR of 31.1%. The global Electric Vehicle Supply Equipment market size was USD 24.52 billion in 2020. Rising initiatives by the governments and increasing focus on the development of charging infrastructure performance are expected to bolster market development. Electric vehicle supply equipment is used extensively to charge electric vehicles (EVs) in commercial and residential locations. It is installed to charge electric vehicle batteries securely and reduce risks. Furthermore, rising initiatives by governments for the promotion of electric vehicle...

Immunodiagnostics Market Size to Hit USD 22,732.7 Million by 2026 | Exhibit a CAGR of 4.7%

Written by Customer Service on March 7, 2022. Posted in Mergers And Acquisitions.

Immunodiagnostics Market growth is boosted by increasing incidence of infectious diseases and rise in geriatric population, technological advancements Pune, India, March 07, 2022 (GLOBE NEWSWIRE) — The increasing number of geriatric population, and occurrences of infectious diseases like cancer, and hepatitis is expected to boost the global immunodiagnostics market. According to a report published by Fortune Business Insights, titled Immunodiagnostics Market Analysis, Insights, and Forecast, 2018-2026, the market was valued at USD 15,777.5 Million in 2017. Fortune Business Insights predicts that the market will rise at a CAGR of 4.7%, and reach USD 22,732.7 Million by the end of 2026. The immune system of a human is one of the most complex networks. Recent advancements in global immunodiagnostics market have improvised diagnosis...

Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 7, 2022. Posted in Earnings Releases And Operating Results.

– Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent – Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate, ITIL-168, in melanoma – Expansion of manufacturing capacity in Manchester, UK, with Tarzana, California facility expected online in 1H 2022 DALLAS, March 07, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its fourth quarter and year end 2021 financial results and provided a corporate update. “I am pleased with our progress in establishing our operational capabilities and initiating a clinical study in our first year as a public company,”...

Groupe BPCE has little exposure to Russia and Ukraine

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Paris, March 7th, 2022 Groupe BPCE has little exposure1 to Russia and Ukraine Groupe BPCE is following developments in the situation in Russia and Ukraine very closely, even though its exposure1 to these two countries is very limited. The Group strictly complies with the regulations in force and diligently implements the necessary measures to strictly apply, as soon as they are published, international sanctions. The Group’s net banking exposures12 amount to:Million euros Net exposure of Groupe BPCE on and off balance sheet12 as of February 28th, 2022Type of exposure Russia UkraineSovereign 0 0Financial institutions 172 0Corporate / structured finance 615 63Total 788 63Net banking exposures12 to Russia correspond mainly to financing activities (733 million euros, or 93% of the...

Allied to Expand Operating Capability in Montréal, Toronto and Vancouver

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Enters into Agreement with Choice Properties to Acquire Urban Office Portfolio for $794 Million and to Issue Exchangeable LP Units at NAV per Unit for 75% of Purchase Price This news release constitutes a “designated news release” for the purposes of Allied’s prospectus supplement dated November 12, 2021, to its short form base shelf prospectus dated June 2, 2021, as amended on November 11, 2021. TORONTO, March 07, 2022 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”)(TSX:AP.UN) announced today that it has entered into an agreement with Choice Properties Real Estate Investment Trust (“Choice Properties”)(TSX:CHP.UN) to acquire the following six urban office properties for $794 million:Property GLA @ Share Occupancy Underground Parking Stalls Certification Principal Tenant1010 Sherbrooke Street...

MINILUXE EXPANDS PILOT ON-DEMAND SERVICE, MINILUXE ANYWHERE, TO NEW MARKETS

Written by Customer Service on March 7, 2022. Posted in Public Companies.

Toronto, Ontario, March 07, 2022 (GLOBE NEWSWIRE) — MiniLuxe, Inc. (“MiniLuxe”) a wholly-owned subsidiary of MiniLuxe Holding Corp (TSXV: MNLX), is pleased to announce the expansion of its on-demand clean nail service MiniLuxe Anywhere. This service gives clients the choice of having MiniLuxe services in studio, or for services to come to a place of convenience for them and is a core part of the company’s strategy to meet the client anywhere and anytime, while empowering its nail designers with the ability to have agency over location, time, and number and types of services for which they would like to book. MiniLuxe first launched its innovative and disruptive Anywhere pilot program in the Dallas, TX market, and with positive momentum and strong client feedback is now expanding its efforts to “Uberize” the industry to the Boston,...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals